<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03376061</url>
  </required_header>
  <id_info>
    <org_study_id>DEPOSITION 1.0 2017-07-28</org_study_id>
    <nct_id>NCT03376061</nct_id>
  </id_info>
  <brief_title>Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery</brief_title>
  <acronym>DEPOSITION</acronym>
  <official_title>DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to conduct a double-blinded single-centre randomized controlled clinical trial of
      application of topical dose of tranexamic acid (TA) versus the usual intravenous TA in
      patients undergoing cardiac surgery at the Hamilton General Hospital. This pilot study will
      assess the feasibility to perform a large randomized international trial exploring this
      objective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative bleeding related to open cardiac surgery increases the rates of complications
      and mortality. It results from the blood thinners that are needed for use. Intravenous
      tranexamic acid (TA) has become a mainstay in cardiac surgical procedures for decreasing
      bleeding and minimizing transfusion requirements. Although intravenous TA is usually well
      tolerated, there is a well-known risk (1 to 4%) of postoperative seizures. This is due to the
      similarity between TA and the brain tissues. The aim is to eliminate the risk of seizures but
      to maintain the protection against bleeding. When TA is used directly on the tissues
      (topically) for other type of surgeries (joints), TA is effective to reduce blood loss and
      transfusions. The aim is to prove that direct application of TA on the heart can eliminate
      postoperative seizures and reduce the amount of blood transfusions in patients who have
      cardiac surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Tranexamic Acid intravenous + Placebo topical versus Placebo intravenous + Tranexamic Acid topical</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The pharmacy will prepare 1 syringe of 50 ml of topical TA (5 g) or placebo. They will also prepare for the same patient 2 syringes of 50 ml (5 g) for intravenous (i.v.) injection or placebo. TA is similar in all aspects to normal saline. Blinding of both teams will be easy. The syringes will be prepared and randomized in pharmacy before the surgery.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative chest tube production 24 hours after surgical procedure</measure>
    <time_frame>24 hours after surgical procedure</time_frame>
    <description>Will be analyzed with a t-test as it is a continuous variable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative seizure development</measure>
    <time_frame>Seizures will be documented from date of surgery to hospital discharge date or date of death for any cause up to hospital discharge date. Whichever came first, up to one month.</time_frame>
    <description>compared via a Fisher's exact test as the frequency will be low</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>All-cause death will be documented from date of surgery through study completion which is 30 days post surgery date.</time_frame>
    <description>compared via a Fisher's exact test as the frequency will be low</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total blood transfusions</measure>
    <time_frame>during surgery</time_frame>
    <description>analyzed by chi-square</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Re-exploration (bleeding/tamponade)</measure>
    <time_frame>Surgical Re-exploration (bleeding/tamponade) will be documented from date of surgery to hospital discharge date or date of death for any cause prior to hospital discharge date. Whichever came first, up to one month.</time_frame>
    <description>compared via a Fisher's exact test as the frequency will be low</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>Number of hours in ICU are being collected at the Post-Operative Visit. Hour collection will start upon arrival at ICU post surgery and stop at ICU exit, up to one month.</time_frame>
    <description>analyzed with a t-test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of TA</measure>
    <time_frame>on arrival in ICU within 3 hours</time_frame>
    <description>analyzed with a t-test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bleeding</condition>
  <condition>Surgical Blood Loss</condition>
  <arm_group>
    <arm_group_label>TA Topical</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 syringe of 50ml of topical Tranexamic Acid (5g) or placebo. The topical will be poured into the pericardial mediastinal cavities in 2 equal doses, 25ml when the pt comes off-pump and the other 25ml before sternotomy is closed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TA Intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 syringes of 50ml (5mg) Tranexamic Acid for intravenous injection or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.</description>
    <arm_group_label>TA Topical</arm_group_label>
    <arm_group_label>TA Intravenous</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt;= 18 years old

          -  Undergoing cardiac surgical procedure with the use of cardiopulmonary bypass and
             median sternotomy

          -  Provide written informed consent

        Exclusion Criteria:

          -  Poor (English) language comprehension

          -  Minimally invasive valve surgery

          -  Off-pump procedures

          -  Emergency operations

          -  Known history of increased bleeding disorder

          -  Thromboembolic disease

          -  Allergy to tranexamic acid

          -  Severe renal impairment (eGFR &lt;30 mL/min/1.73m2 )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre Lamy, MD MHSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingrid Copland, CCRA</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40368</phone_ext>
    <email>cogency@phri.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Copland</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>40368</phone_ext>
      <email>cogency@phri.ca</email>
    </contact>
    <investigator>
      <last_name>Andre Lamy, MD MHSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lloyd Semelhago, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Kucuk O, Kwaan HC, Frederickson J, Wade L, Green D. Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation. Am J Hematol. 1986 Nov;23(3):223-9.</citation>
    <PMID>3766524</PMID>
  </reference>
  <reference>
    <citation>Harker LA, Malpass TW, Branson HE, Hessel EA 2nd, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980 Nov;56(5):824-34.</citation>
    <PMID>6448643</PMID>
  </reference>
  <reference>
    <citation>Despotis GJ, Santoro SA, Spitznagel E, Kater KM, Cox JL, Barnes P, Lappas DG. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1994 Jan;107(1):271-9.</citation>
    <PMID>8283896</PMID>
  </reference>
  <reference>
    <citation>Lemmer JH Jr, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg. 1994 Feb;107(2):543-51; discussion 551-3.</citation>
    <PMID>7508070</PMID>
  </reference>
  <reference>
    <citation>Santos AT, Kalil RA, Bauemann C, Pereira JB, Nesralla IA. A randomized, double-blind, and placebo-controlled study with tranexamic acid of bleeding and fibrinolytic activity after primary coronary artery bypass grafting. Braz J Med Biol Res. 2006 Jan;39(1):63-9. Epub 2005 Dec 15.</citation>
    <PMID>16400465</PMID>
  </reference>
  <reference>
    <citation>Pleym H, Stenseth R, Wahba A, Bjella L, Karevold A, Dale O. Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery. Anesth Analg. 2003 Apr;96(4):923-8, table of contents.</citation>
    <PMID>12651635</PMID>
  </reference>
  <reference>
    <citation>Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussi√®res JS, McGuinness S, Byrne K, Chan MT, Landoni G, Wallace S; ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med. 2017 Jan 12;376(2):136-148. doi: 10.1056/NEJMoa1606424. Epub 2016 Oct 23. Erratum in: N Engl J Med. 2018 Feb 22;378(8):782.</citation>
    <PMID>27774838</PMID>
  </reference>
  <reference>
    <citation>Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg. 2008 Dec;107(6):1783-90. doi: 10.1213/ane.0b013e318184bc20.</citation>
    <PMID>19020118</PMID>
  </reference>
  <reference>
    <citation>Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thorac Surg. 2012 Jan;93(1):148-54. doi: 10.1016/j.athoracsur.2011.07.085. Epub 2011 Nov 4.</citation>
    <PMID>22054656</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

